Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

This study is looking at how two HIV medications — dolutegravir and rilpivirine (taken together as a single pill) — behave in the bodies of children aged 6 to under 12 years. Researchers want to understand safety, tolerability, and how the drugs are processed in younger patients. **You may be eligible if...** - Your child is between 6 and under 12 years old and has confirmed HIV-1 infection - Your child weighs at least 25 kg (about 55 lbs) - Your child has been on the same HIV treatment regimen for at least the past 6 months - Your child's HIV viral load is undetectable (under 50 copies/mL) at screening **You may NOT be eligible if...** - Your child has ever had resistance to the class of HIV drugs called NNRTIs or integrase inhibitors - Your child has had a change in HIV treatment due to the virus not being controlled - Your child has serious heart, liver, or kidney problems - Your child has active hepatitis B infection or an untreated hepatitis C infection - Your child is pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.